利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.018 秒)

    Treatment of various ailments
    2.
    发明申请
    Treatment of various ailments 审中-公开
    治疗各种疾病

    公开(公告)号：US20150246229A1

    公开(公告)日：2015-09-03

    申请号：US14545472

    申请日：2015-05-07

    申请人： Donald Alan Rhodes

    发明人： Donald Alan Rhodes

    IPC分类号： A61N1/36 ,  A61N1/08

    CPC分类号： A61N1/36014 ,  A61N1/0456 ,  A61N1/08 ,  A61N1/36025

    摘要： A method of treating a wide variety of heretofore considered unrelated ailments comprises delivering electricity through a circuit in the body. The circuit includes at least four nerves leading from at least two of the patient's extremities to various nerve roots adjacent the spinal column. Electrical energy from an electrical interferential therapy device is delivered though electrodes on the extremities adjacent the nerve endings until symptoms of the diagnosed ailment ameliorate. Sending impulses from the periphery to the central nervous system, appears to help the body manufacture various neuropeptides and other chemicals, which control the essential basics of the body's health and well being.

    摘要翻译： 一种治疗多种以前被认为是无关疾病的方法包括通过身体中的电路输送电力。 电路包括从患者四肢中的至少两个引导到邻近脊柱的各种神经根的至少四个神经。 来自电干扰治疗装置的电能通过邻近神经末梢的四肢上的电极传递，直到诊断出的疾病的症状改善。 从外围向中枢神经系统发送冲动，似乎有助于身体制造各种神经肽和其他化学物质，从而控制身体健康和福祉的基本要素。

    Method for the extraction of sesquiterpene lactones
    4.
    发明授权
    Method for the extraction of sesquiterpene lactones 失效
    提取倍半萜内酯的方法

    公开(公告)号：US5384121A

    公开(公告)日：1995-01-24

    申请号：US87672

    申请日：1993-07-08

    申请人： Alan Rhodes

    发明人： Alan Rhodes

    IPC分类号： A61K31/365 ,  A61K31/34 ,  A61K36/00 ,  A61K36/28 ,  C07D493/04 ,  A61K35/78

    CPC分类号： C07D493/04 ,  A61K36/28

    摘要： The present invention relates to a method for the extraction of sesquiterpene lactones from the plant Tanacetum parthenium specifically using polar organic solvents and the use of such extracts in pharmaceutical products. It has been found that by utilization of an extraction procedure in accordance with the current invention, a significantly greater amount of the sesquiterpene lactone parthenolide is extracted from Tanacetum parthenium than is the case when using petroleum spirit as the primary extractant, the solvent usually used in previous studies.

    摘要翻译： PCT No.PCT / GB92 / 00036 Sec。 371日期：1993年7月8日 102（e）日期1993年7月8日PCT提交1992年1月8日PCT公布。 第WO92 / 11857号公报 日本1992年7月23日。本发明涉及一种特异性使用极性有机溶剂从植物丹参醇中提取倍半萜内酯的方法，以及在药品中使用这些提取物。 已经发现，通过利用根据本发明的提取方法，与使用石油醚作为主要萃取剂的情况相比，从Tanacetum铼中提取显着更多量的倍半萜内酯单酚酯，溶剂通常用于 以前的研究。

    Apparatus for determining optimum treatment parameters
    6.
    发明授权
    Apparatus for determining optimum treatment parameters 有权

    公开(公告)号：US09333348B2

    公开(公告)日：2016-05-10

    申请号：US14545819

    申请日：2015-06-22

    申请人： Donald Alan Rhodes

    发明人： Donald Alan Rhodes

    IPC分类号： A61N1/36 ,  A61B5/00 ,  A61N1/08 ,  A61N1/32 ,  G06F19/00

    CPC分类号： A61N1/36014 ,  A61B5/4035 ,  A61B5/4836 ,  A61N1/08 ,  A61N1/323 ,  G06F19/3481 ,  G16H40/63

    摘要： A diagnostic device in an electrical interferential treatment regime applies different pulse frequencies in one selection of electrode placement and determines the change of blood flow in response to the change in pulse frequency in an attempt to determine an optimum or workable set of parameters. The device includes electronic storage to record a series of tests and their results and a communication link. The communication link enables a professional caregiver to determine whether the parameter determinations, made at a location remote from the professional's office, such as at the residence of the patient, were conducted and were conducted correctly. The communication link also enables the professional to determine whether the treatments were conducted and conducted correctly.

    RAPAMYCIN CARBONATE ESTERS
    8.
    发明申请
    RAPAMYCIN CARBONATE ESTERS 审中-公开
    RAPAMYCIN碳酸钙

    公开(公告)号：US20090253733A1

    公开(公告)日：2009-10-08

    申请号：US12061416

    申请日：2008-04-02

    申请人： Alan Rhodes ,  Shivpal S. Sandhu ,  Simon J. Onis ,  John E. Mckendrick

    发明人： Alan Rhodes ,  Shivpal S. Sandhu ,  Simon J. Onis ,  John E. Mckendrick

    IPC分类号： A61K31/439 ,  C07D498/18 ,  C12P17/18

    CPC分类号： C07D498/18

    摘要： Certain embodiments include carbonate esters of rapamycin at position 42 that are synthesized by a lipase catalyzed regio-specific process. These compounds or a pharmaceutically acceptable salt thereof are useful in the treatment of organ and tissue transplant rejection, autoimmune disease, proliferative disorder, restenosis, cancer, or microbial infection.

    摘要翻译： 某些实施方案包括通过脂肪酶催化的区域特异性方法合成的位置42的雷帕霉素的碳酸酯。 这些化合物或其药学上可接受的盐可用于治疗器官和组织移植排斥，自身免疫疾病，增殖性疾病，再狭窄，癌症或微生物感染。

    Slow release formulation
    9.
    发明授权
    Slow release formulation 失效
    缓释制剂

    公开(公告)号：US4880830A

    公开(公告)日：1989-11-14

    申请号：US012026

    申请日：1987-02-09

    申请人： Alan Rhodes

    发明人： Alan Rhodes

    IPC分类号： A61K47/44 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K9/26 ,  A61K47/00 ,  A61K47/36

    CPC分类号： A61K9/2077 ,  Y10S514/965

    摘要： A slow release formulation to be administered to humans or animals, comprising primary granules which contain an active ingredient and are in a secondary matrix of a water soluble/dispersible slow release material, the granules themselves comprising particles containing the active ingredients and in a primary matrix of a water soluble/dispersible slow release material.Optionally the formulation comprises a binder phase of a water insoluble slow release material having embedded therein secondary granules comprising the secondary matrix containing the primary matrix granules.The water soluble/dispersible material may be a polysaccharide and acacia and low viscosity methylcellulose are exemplified, as well as alginate and gelatine.

    摘要翻译： 给予人或动物的缓释制剂，包含含有活性成分并且在水溶性/可分散缓释材料的次级基质中的初级颗粒，颗粒本身包含含有活性成分的颗粒和主要基质 的水溶性/分散缓释材料。 任选地，制剂包含水不溶性慢释放材料的粘结相，其中嵌入有包含主基质颗粒的次级基质的次级颗粒。 水溶性/分散性材料可以是多糖和阿拉伯树胶，低粘度甲基纤维素也是藻酸盐和明胶。

    Preparation for percutaneous administration
    10.
    发明授权
    Preparation for percutaneous administration 失效
    经皮给药制剂

    公开(公告)号：US4654209A

    公开(公告)日：1987-03-31

    申请号：US765451

    申请日：1985-08-14

    申请人： Stewart T. Leslie ,  Alan Rhodes ,  Cyril Boroda ,  Alfred Halpern

    发明人： Stewart T. Leslie ,  Alan Rhodes ,  Cyril Boroda ,  Alfred Halpern

    IPC分类号： A61K9/107 ,  A61K31/21 ,  A61K31/79

    CPC分类号： A61K9/107 ,  A61K31/21 ,  Y10S514/947 ,  Y10S514/97

    摘要： A preparation for percutaneous administration of nitroglycerine, said preparation comprising nitroglycerine incorporated in a cream base in an amount not less than about 0.05% by weight based on the total weight of the preparation. The composition may also contain other medicaments, the bioavailability of which is enhanced by the nitroglycerine. The action of the preparation against for example angina may be brought about by having an appropriate amount of nitroglycerine or as additional medicament another medicament active against angina. The preparation may contain an hydroxyalkylcellulose which may provide, in combination with a waxy component in the cream, for example a higher aliphatic alcohol, a prolonged release effect. The preparation has advantages particularly as regards bioavailability over prior uniphasic ointments.